Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 18 | 2021 | 138 | 2.380 |
Why?
|
| Antibodies, Viral | 6 | 2022 | 87 | 1.520 |
Why?
|
| Immunoglobulin G | 8 | 2022 | 129 | 1.460 |
Why?
|
| Immunoglobulins, Intravenous | 4 | 2018 | 16 | 1.050 |
Why?
|
| Antibody Formation | 2 | 2022 | 40 | 1.040 |
Why?
|
| Salivary alpha-Amylases | 1 | 2023 | 1 | 0.920 |
Why?
|
| Viral Vaccines | 1 | 2022 | 5 | 0.890 |
Why?
|
| Vaccines | 1 | 2022 | 12 | 0.890 |
Why?
|
| Immunologic Deficiency Syndromes | 3 | 2017 | 10 | 0.860 |
Why?
|
| Agammaglobulinemia | 2 | 2018 | 2 | 0.820 |
Why?
|
| Common Variable Immunodeficiency | 2 | 2018 | 5 | 0.820 |
Why?
|
| Bacterial Infections | 3 | 2018 | 69 | 0.780 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2018 | 1 | 0.650 |
Why?
|
| Immunoglobulins | 1 | 2017 | 28 | 0.620 |
Why?
|
| Child, Preschool | 12 | 2019 | 642 | 0.610 |
Why?
|
| Immunotherapy | 1 | 2017 | 62 | 0.600 |
Why?
|
| Immunologic Factors | 1 | 2017 | 39 | 0.600 |
Why?
|
| Biomarkers | 6 | 2023 | 689 | 0.570 |
Why?
|
| Fluticasone | 4 | 2019 | 5 | 0.560 |
Why?
|
| Humans | 39 | 2023 | 29337 | 0.550 |
Why?
|
| Child | 12 | 2021 | 1346 | 0.510 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2019 | 100 | 0.490 |
Why?
|
| Glucocorticoids | 4 | 2019 | 67 | 0.470 |
Why?
|
| Precision Medicine | 3 | 2021 | 24 | 0.440 |
Why?
|
| Respiratory Sounds | 2 | 2019 | 9 | 0.420 |
Why?
|
| Bronchodilator Agents | 3 | 2019 | 14 | 0.400 |
Why?
|
| Adolescent | 9 | 2019 | 2279 | 0.370 |
Why?
|
| Female | 22 | 2021 | 16197 | 0.370 |
Why?
|
| Male | 21 | 2021 | 15621 | 0.370 |
Why?
|
| Salmeterol Xinafoate | 2 | 2019 | 3 | 0.360 |
Why?
|
| Alendronate | 2 | 2019 | 8 | 0.350 |
Why?
|
| Adult | 13 | 2021 | 8601 | 0.350 |
Why?
|
| Ibuprofen | 2 | 2021 | 12 | 0.350 |
Why?
|
| NF-kappa B | 3 | 2022 | 107 | 0.320 |
Why?
|
| Double-Blind Method | 9 | 2021 | 503 | 0.310 |
Why?
|
| Saliva | 2 | 2023 | 53 | 0.310 |
Why?
|
| Young Adult | 6 | 2019 | 1932 | 0.310 |
Why?
|
| Middle Aged | 10 | 2021 | 9823 | 0.300 |
Why?
|
| Anti-Asthmatic Agents | 4 | 2018 | 21 | 0.300 |
Why?
|
| Administration, Inhalation | 7 | 2019 | 25 | 0.280 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 27 | 0.270 |
Why?
|
| Eosinophilia | 2 | 2017 | 47 | 0.240 |
Why?
|
| Cockroaches | 1 | 2003 | 3 | 0.240 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2003 | 5 | 0.240 |
Why?
|
| Allergens | 1 | 2003 | 22 | 0.240 |
Why?
|
| Acetaminophen | 3 | 2021 | 22 | 0.230 |
Why?
|
| Nucleocapsid | 1 | 2022 | 3 | 0.230 |
Why?
|
| Neutralization Tests | 1 | 2022 | 10 | 0.220 |
Why?
|
| beta-Glucans | 1 | 2022 | 25 | 0.220 |
Why?
|
| Sputum | 2 | 2019 | 23 | 0.210 |
Why?
|
| Health Personnel | 1 | 2022 | 115 | 0.200 |
Why?
|
| Pandemics | 2 | 2021 | 236 | 0.200 |
Why?
|
| Infant | 6 | 2018 | 531 | 0.200 |
Why?
|
| Lung | 2 | 2019 | 154 | 0.190 |
Why?
|
| Immunity, Innate | 1 | 2021 | 90 | 0.190 |
Why?
|
| Prospective Studies | 4 | 2019 | 1811 | 0.190 |
Why?
|
| Cohort Studies | 3 | 2021 | 1939 | 0.180 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 2 | 0.180 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 45 | 0.180 |
Why?
|
| Hypersensitivity | 1 | 2020 | 48 | 0.180 |
Why?
|
| Tiotropium Bromide | 1 | 2019 | 2 | 0.180 |
Why?
|
| Mometasone Furoate | 1 | 2019 | 6 | 0.180 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2019 | 5 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 340 | 0.170 |
Why?
|
| Vitamin A Deficiency | 1 | 2018 | 1 | 0.170 |
Why?
|
| Vitamin A | 1 | 2018 | 7 | 0.170 |
Why?
|
| Contrast Sensitivity | 1 | 2018 | 8 | 0.170 |
Why?
|
| Eosinophils | 1 | 2019 | 47 | 0.170 |
Why?
|
| Betacoronavirus | 1 | 2020 | 75 | 0.170 |
Why?
|
| Zinc | 1 | 2018 | 35 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 31 | 0.160 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 1442 | 0.160 |
Why?
|
| Glutathione | 1 | 2018 | 30 | 0.160 |
Why?
|
| Arginine | 1 | 2018 | 18 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 86 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 89 | 0.160 |
Why?
|
| Leukotriene Antagonists | 1 | 2016 | 1 | 0.150 |
Why?
|
| Inhalation Exposure | 2 | 2008 | 6 | 0.150 |
Why?
|
| Treatment Outcome | 4 | 2018 | 3478 | 0.140 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 553 | 0.140 |
Why?
|
| Azithromycin | 1 | 2015 | 4 | 0.140 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 22 | 0.140 |
Why?
|
| Postoperative Complications | 1 | 2022 | 957 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2015 | 64 | 0.130 |
Why?
|
| Research Design | 3 | 2021 | 212 | 0.130 |
Why?
|
| HIV Infections | 1 | 2022 | 970 | 0.130 |
Why?
|
| Pregnenediones | 1 | 2014 | 3 | 0.130 |
Why?
|
| Vitamins | 1 | 2014 | 17 | 0.120 |
Why?
|
| Cholecalciferol | 1 | 2014 | 6 | 0.120 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 10 | 0.120 |
Why?
|
| Recurrence | 3 | 2016 | 350 | 0.120 |
Why?
|
| Cotinine | 2 | 2011 | 5 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 402 | 0.110 |
Why?
|
| Quality of Life | 1 | 2017 | 662 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 437 | 0.110 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 2023 | 28 | 0.110 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 1113 | 0.100 |
Why?
|
| Pruritus | 1 | 2011 | 7 | 0.100 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2011 | 7 | 0.100 |
Why?
|
| Silicones | 1 | 2011 | 8 | 0.100 |
Why?
|
| Peritoneal Dialysis | 1 | 2011 | 23 | 0.100 |
Why?
|
| Catheters, Indwelling | 1 | 2011 | 25 | 0.100 |
Why?
|
| Mexican Americans | 1 | 2011 | 28 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 1830 | 0.100 |
Why?
|
| Smoking | 1 | 2011 | 194 | 0.090 |
Why?
|
| Prevalence | 2 | 2018 | 487 | 0.090 |
Why?
|
| Inflammation | 2 | 2022 | 344 | 0.090 |
Why?
|
| Cross-Over Studies | 2 | 2019 | 78 | 0.090 |
Why?
|
| Aged | 3 | 2018 | 9448 | 0.090 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2008 | 7 | 0.080 |
Why?
|
| Leukocyte Count | 2 | 2019 | 92 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2021 | 638 | 0.080 |
Why?
|
| Albuterol | 2 | 2018 | 15 | 0.080 |
Why?
|
| Models, Biological | 1 | 2008 | 343 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 959 | 0.070 |
Why?
|
| Acetates | 1 | 2005 | 19 | 0.070 |
Why?
|
| Quinolines | 1 | 2005 | 16 | 0.070 |
Why?
|
| Incidence | 2 | 2018 | 756 | 0.060 |
Why?
|
| Pyroglyphidae | 1 | 2003 | 3 | 0.060 |
Why?
|
| Air Pollution, Indoor | 1 | 2003 | 3 | 0.060 |
Why?
|
| Skin Tests | 1 | 2003 | 14 | 0.060 |
Why?
|
| Urban Health | 1 | 2003 | 23 | 0.060 |
Why?
|
| Child Welfare | 1 | 2003 | 17 | 0.060 |
Why?
|
| Cats | 1 | 2003 | 76 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2003 | 113 | 0.060 |
Why?
|
| Dogs | 1 | 2003 | 253 | 0.060 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2023 | 4 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2022 | 482 | 0.060 |
Why?
|
| Hepatitis B Antibodies | 1 | 2022 | 1 | 0.060 |
Why?
|
| Hepatitis B e Antigens | 1 | 2022 | 1 | 0.060 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2022 | 10 | 0.060 |
Why?
|
| Antibodies | 1 | 2023 | 65 | 0.060 |
Why?
|
| Syk Kinase | 1 | 2022 | 10 | 0.060 |
Why?
|
| Killer Cells, Natural | 1 | 2023 | 91 | 0.050 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2002 | 1 | 0.050 |
Why?
|
| Lectins, C-Type | 1 | 2022 | 106 | 0.050 |
Why?
|
| Chemokines | 1 | 2002 | 29 | 0.050 |
Why?
|
| Serologic Tests | 1 | 2022 | 15 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 25 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2021 | 34 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2002 | 100 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2021 | 65 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2021 | 20 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 20 | 0.050 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2021 | 9 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 19 | 0.050 |
Why?
|
| Complement Activation | 1 | 2021 | 13 | 0.050 |
Why?
|
| Receptors, Fc | 1 | 2021 | 11 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2021 | 50 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 17 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2021 | 55 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 215 | 0.050 |
Why?
|
| United States | 2 | 2018 | 2333 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2014 | 140 | 0.050 |
Why?
|
| Education, Distance | 1 | 2020 | 18 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2019 | 82 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 12 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 42 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 788 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2019 | 78 | 0.040 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2018 | 1 | 0.040 |
Why?
|
| Ornithine | 1 | 2018 | 3 | 0.040 |
Why?
|
| Growth | 1 | 2018 | 5 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2003 | 1184 | 0.040 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2018 | 17 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 770 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 2017 | 8 | 0.040 |
Why?
|
| Immunoglobulin E | 1 | 2017 | 15 | 0.040 |
Why?
|
| Chicago | 2 | 2011 | 865 | 0.040 |
Why?
|
| Fever | 1 | 2016 | 40 | 0.040 |
Why?
|
| Neutrophils | 1 | 2017 | 117 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 162 | 0.040 |
Why?
|
| Phenotype | 1 | 2017 | 355 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2015 | 53 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 223 | 0.030 |
Why?
|
| Animals | 1 | 2003 | 4552 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 159 | 0.030 |
Why?
|
| Pain | 1 | 2016 | 391 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 787 | 0.030 |
Why?
|
| Patch Tests | 1 | 2011 | 2 | 0.030 |
Why?
|
| Exanthema | 1 | 2011 | 15 | 0.030 |
Why?
|
| Morbidity | 1 | 2011 | 63 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 298 | 0.020 |
Why?
|
| Half-Life | 1 | 2009 | 18 | 0.020 |
Why?
|
| Drug Dosage Calculations | 1 | 2009 | 6 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2009 | 52 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 161 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 328 | 0.020 |
Why?
|
| Sulfides | 1 | 2005 | 12 | 0.020 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2005 | 17 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2005 | 25 | 0.020 |
Why?
|
| Placebos | 1 | 2005 | 77 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2002 | 11 | 0.010 |
Why?
|
| Free Radical Scavengers | 1 | 2002 | 12 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 145 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2002 | 73 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2002 | 48 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2002 | 132 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 625 | 0.010 |
Why?
|